Table 2.
LYNX1 expression associated with clinicopathological characteristics (logistic regression).
| Characteristics | Total (N) | Odds ratio in LYNX1expression | p value |
|---|---|---|---|
| Clinical stage (stage I/II vs. stage III/IV) | 373 | 0.92 (0.39–2.15) | 0.84 |
| Primary therapy outcome (SD-PD vs. PR-CR) | 302 | 0.85 (0.46–1.57) | 0.604 |
| Cancer status (tumor free vs. with tumor) | 331 | 1.22 (0.74–2) | 0.433 |
| Histologic grade (G1G2 vs. G3G4) | 366 | 1.05 (0.56–2) | 0.871 |
| Tumor residual disease (NRD vs. RD) | 333 | 2.08 (1.2–3.67) | 0.01 |
| Anatomic neoplasm subdivision (unilateral vs. bilateral) | 354 | 0.82 (0.51–1.3) | 0.391 |
| Age (<60 vs. ≥60) | 376 | 0.55 (0.36–0.82) | 0.004 |
SD: stable disease; PD: progressive disease; PR: partial remission; CR: complete remission; NRD: no residual disease; RD: residual disease.